Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 6/20 | 0.33 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 2/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718723 | 0.90 | HCAR1 (0.39) | MAP4K1KRASSOS1HCAR1 | |
| SCHEMBL9988615 | 0.86 | — | — | |
| SCHEMBL589967 | 0.81 | BMPR1B (0.35) | — | |
| SCHEMBL14718456 | 0.78 | BMPR1B (0.38) | ATRHCAR1 | |
| SCHEMBL22655381 | 0.78 | BMPR1B (0.38) | HCAR1 | |
| SCHEMBL3803722 | 0.76 | MAP4K1 (0.37) | MAP4K1PIK3CAHTR3AIL4I1KRAS | |
| SCHEMBL3790993 | 0.76 | MAP4K1 (0.37) | MAP4K1PIK3CAHTR3AIL4I1KRAS | |
| SCHEMBL3790997 | 0.76 | MAP4K1 (0.37) | MAP4K1PIK3CAHTR3AIL4I1KRAS | |
| SCHEMBL20709985 | 0.74 | PIK3CA (0.42) | MAP4K1PIK3CAHTR3A | |
| SCHEMBL925592 | 0.73 | IL4I1 (0.41) | MAP4K1HTR3AIL4I1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185584-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | Capulus Therapeutics, LLC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| CN-111635408-B | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3849983-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| CN-112279852-A | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| CN-111635408-A | Triazolo-pyrimidine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-111601809-A | Triazolo-pyrimidine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2020052631-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | MAP4K1 1776/4885ADORA2A 1/4885ADORA2B 3/4885 |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | MAP4K1 1776/4885ADORA2A 1/4885ADORA2B 3/4885 |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | MAP4K1 1776/4885ADORA2A 1/4885ADORA2B 3/4885 |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | MAP4K1 1776/4885ADORA2A 1/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.